CL2020002621A1 - Composiciones de proteína de fusión recombinante neuregulina-1 (nrg-1) humana y métodos para su uso - Google Patents

Composiciones de proteína de fusión recombinante neuregulina-1 (nrg-1) humana y métodos para su uso

Info

Publication number
CL2020002621A1
CL2020002621A1 CL2020002621A CL2020002621A CL2020002621A1 CL 2020002621 A1 CL2020002621 A1 CL 2020002621A1 CL 2020002621 A CL2020002621 A CL 2020002621A CL 2020002621 A CL2020002621 A CL 2020002621A CL 2020002621 A1 CL2020002621 A1 CL 2020002621A1
Authority
CL
Chile
Prior art keywords
fusion protein
recombinant fusion
nrg
methods
protein compositions
Prior art date
Application number
CL2020002621A
Other languages
English (en)
Spanish (es)
Inventor
John Li
Shengwei Li
Dixiang Luo
Yiran Wu
Ming Zhou
Xiaolei Zhuang
Liang Hua
Pengyi Luo
Yang Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66484143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2020002621(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of CL2020002621A1 publication Critical patent/CL2020002621A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
CL2020002621A 2018-04-11 2020-10-09 Composiciones de proteína de fusión recombinante neuregulina-1 (nrg-1) humana y métodos para su uso CL2020002621A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862656246P 2018-04-11 2018-04-11

Publications (1)

Publication Number Publication Date
CL2020002621A1 true CL2020002621A1 (es) 2021-06-11

Family

ID=66484143

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002621A CL2020002621A1 (es) 2018-04-11 2020-10-09 Composiciones de proteína de fusión recombinante neuregulina-1 (nrg-1) humana y métodos para su uso

Country Status (25)

Country Link
US (3) US11046741B2 (https=)
EP (2) EP3774859B1 (https=)
JP (3) JP7575272B2 (https=)
KR (1) KR102949228B1 (https=)
CN (2) CN113166218B (https=)
AU (2) AU2019252262B2 (https=)
BR (1) BR112020020646A2 (https=)
CA (1) CA3096420A1 (https=)
CL (1) CL2020002621A1 (https=)
CO (1) CO2020012621A2 (https=)
DK (1) DK3774859T3 (https=)
EA (1) EA202092458A1 (https=)
ES (1) ES2980163T3 (https=)
FI (1) FI3774859T3 (https=)
HU (1) HUE066892T2 (https=)
IL (2) IL322374A (https=)
MX (2) MX2020010740A (https=)
MY (1) MY204230A (https=)
PE (1) PE20210111A1 (https=)
PH (1) PH12020551648A1 (https=)
PL (1) PL3774859T3 (https=)
PT (1) PT3774859T (https=)
SG (1) SG11202009831UA (https=)
TW (2) TWI888027B (https=)
WO (1) WO2019200033A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20210111A1 (es) 2018-04-11 2021-01-19 Salubris Biotherapeutics Inc Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
AU2020348436A1 (en) * 2019-09-16 2022-04-07 Zensun (Shanghai) Science & Technology, Co., Ltd. Recombinant human neuregulin derivatives and use thereof
CN114420310B (zh) * 2022-01-18 2024-11-12 河南大学 基于图转换网络的药物ATC Code预测方法
WO2023178086A1 (en) * 2022-03-15 2023-09-21 Salubris Biotherapeutics, Inc. Methods of treating fibrosis and arrhythmia with a neuregulin-1 fusion protein
CN116832040B (zh) * 2023-06-12 2026-01-13 北京市心肺血管疾病研究所 细胞周期蛋白依赖性激酶抑制剂在治疗射血分数保留型心力衰竭中的应用
WO2025122581A1 (en) * 2023-12-08 2025-06-12 The Trustees Of Indiana University Compositions comprising neuregulin and methods of using the same to treat or prevent neurotrophic keratitis
WO2025245112A1 (en) 2024-05-21 2025-11-27 Salubris Biotherapeutics, Inc. Neuregulin-1/anti-her3 antibody fusion protein for use in the treatment of heart failure

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
IL101943A0 (en) * 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
AUPP785098A0 (en) * 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
WO2003099320A1 (en) * 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
EP1824879B1 (en) 2004-07-09 2014-10-29 Wayne State University HYBRID PROTEINS WITH ErbB4 EXTRACELLULAR DOMAIN AND NEUREGULIN HEPARIN-BINDING DOMAIN FOR TARGETING
US8053569B2 (en) * 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
BRPI0818033A2 (pt) 2007-10-16 2015-03-24 Symphogen As Composições compreendendo multímeros otimizados de her1 e her3 e métodos para usos dos mesmos
WO2009114110A1 (en) * 2008-03-08 2009-09-17 Immungene, Inc. Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
WO2010006059A1 (en) * 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 binding proteins and uses thereof
JP5743898B2 (ja) 2008-11-28 2015-07-01 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド ニューレグリンペプチド及びその使用
JP2013507378A (ja) * 2009-10-09 2013-03-04 メルク・シャープ・エンド・ドーム・コーポレイション 抗ｈｅｒ３抗体の製造、特徴づけ及びその用途
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
US9029328B2 (en) 2010-03-24 2015-05-12 The Brigham And Women's Hospital, Inc. Methods for cardioprotection and cardioregeneration with dimers of EGF family ligands
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
CA2929386C (en) * 2013-11-07 2023-01-03 Inserm (Institut National De La Sante Et De La Recherche Medicale) Neuregulin allosteric anti-her3 antibody
CN104758922A (zh) 2014-01-03 2015-07-08 上海泽生科技开发有限公司 纽兰格林制剂的配方
KR102399277B1 (ko) * 2014-04-10 2022-05-18 다이이찌 산쿄 가부시키가이샤 항her3 항체-약물 콘주게이트
CA2959716A1 (en) * 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Anti-her3 antibodies and uses of same
CN105561298A (zh) * 2014-10-17 2016-05-11 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
RU2767329C2 (ru) 2016-02-06 2022-03-17 Эпимаб Биотерапьютикс, Инк. Иммуноглобулин с тандемными fab-фрагментами и варианты его применения
CN110167968B (zh) 2016-09-15 2023-11-28 斯图加特大学 针对her3的抗原结合蛋白
PE20210111A1 (es) 2018-04-11 2021-01-19 Salubris Biotherapeutics Inc Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso

Also Published As

Publication number Publication date
TWI888027B (zh) 2025-06-21
MY204230A (en) 2024-08-16
CO2020012621A2 (es) 2020-12-21
EP4361177A2 (en) 2024-05-01
CN118909141A (zh) 2024-11-08
US20210347841A1 (en) 2021-11-11
DK3774859T3 (da) 2024-05-27
CA3096420A1 (en) 2019-10-17
JP7631420B2 (ja) 2025-02-18
TW202426470A (zh) 2024-07-01
HUE066892T2 (hu) 2024-09-28
WO2019200033A1 (en) 2019-10-17
TWI834654B (zh) 2024-03-11
US20230322877A1 (en) 2023-10-12
ES2980163T3 (es) 2024-09-30
IL322374A (en) 2025-09-01
CN113166218B (zh) 2024-08-13
JP2021535727A (ja) 2021-12-23
SG11202009831UA (en) 2020-11-27
BR112020020646A2 (pt) 2021-02-23
JP2023134436A (ja) 2023-09-27
US11046741B2 (en) 2021-06-29
US11718652B2 (en) 2023-08-08
MX2020010740A (es) 2021-01-20
KR20210022542A (ko) 2021-03-03
CN113166218A (zh) 2021-07-23
MX2025002112A (es) 2025-05-02
IL277790B2 (en) 2026-01-01
IL277790B1 (en) 2025-09-01
AU2019252262A1 (en) 2020-10-22
PH12020551648A1 (en) 2021-07-26
FI3774859T3 (fi) 2024-05-24
AU2023285793A1 (en) 2024-01-18
KR102949228B1 (ko) 2026-04-06
TW201945389A (zh) 2019-12-01
JP7575272B2 (ja) 2024-10-29
EP3774859A1 (en) 2021-02-17
EP4361177A3 (en) 2024-08-14
NZ768694A (en) 2024-10-25
JP2025072502A (ja) 2025-05-09
PT3774859T (pt) 2024-05-27
PE20210111A1 (es) 2021-01-19
AU2019252262B2 (en) 2023-10-05
EP3774859B1 (en) 2024-03-13
PL3774859T3 (pl) 2024-10-14
US20200010522A1 (en) 2020-01-09
EA202092458A1 (ru) 2021-02-08
IL277790A (en) 2020-11-30
AU2023285793B2 (en) 2026-01-22

Similar Documents

Publication Publication Date Title
CL2020002621A1 (es) Composiciones de proteína de fusión recombinante neuregulina-1 (nrg-1) humana y métodos para su uso
CL2020003096A1 (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
CL2021003327A1 (es) Anticuerpos anti - sortilina y métodos para su uso. (divisional de solicitud 202100089).
AR106991A1 (es) Anticuerpos neutralizantes del virus de inmunodeficiencia humana
BR112022009273A2 (pt) Imunoglobulinas modificadas para direcionar depósitos amiloides
BR112019008010A2 (pt) anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica
PE20180120A1 (es) Proteinas de union a icos
IL259940B2 (en) Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
PE20091449A1 (es) Proteinas de union a antigenos
BR112019008351A2 (pt) imunoglobulinas e usos das mesmas
CL2008002668A1 (es) Anticuerpo que se une especificamente al polipeptido de linfopoyetina estromal timica (tslp); composicion farmaceutica que lo comprende; acido nucleico, vector de expresion, celula que lo comprende; hibridoma; metodo de produccion del anticuerpo; uso para tratar desorden inflamatorio relacionado a tslp o condicion fibrotica relacionada a tslp.
BRPI0821168B8 (pt) anticorpo isolado que se liga ao il-21 humano, ou um fragmento deste, usos de dito anticorpo ou fragmento, e, hibridoma
HRP20231650T1 (hr) Cjepivo u kombinaciji sa inhibitorom imunološke kontrolne točke za primjenu u liječenju raka
CL2022000230A1 (es) Anticuerpos anti-ms4a4a y métodos de uso de los mismos
CL2024003891A1 (es) Anticuerpo multiespecífico; composición farmacéutica; y su uso.
MX421763B (es) Metodos y composiciones que comprenden proteina d tensoactiva (sp-d)
EP4613334A3 (en) Her-2 binding antibodies
AR133188A1 (es) ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG
AR119536A1 (es) Anticuerpos anti-ms4a4a y métodos de uso de los mismos
AR122237A1 (es) Anticuerpos anti-sortilina y métodos para su uso
NZ768694B2 (en) Human neuregulin-1 (nrg-1) recombinant fusion protein compositions and methods of use thereof
EA201992324A1 (ru) Анти-trem2 антитела и способы их применения
AR103529A1 (es) Proteína de unión a icos o porción de unión al antígeno de la misma, anticuerpo monoclonal de la misma y composición farmacéutica que lo comprende
AR104818A1 (es) Combinaciones y usos y tratamientos relacionados con las mismas